Timing of kidney surgery with immunotherapy for advanced renal cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two treatment plans for advanced kidney cancer: having surgery to remove the kidney tumor right away along with immunotherapy drugs (ipilimumab and nivolumab), versus starting the immunotherapy first and doing surgery later. The goal is to see if delaying surgery is just as good or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have a type of kidney cancer called clear cell renal cell carcinoma that has spread to other parts of your body (metastatic).
- You are generally able to take care of yourself and do light activities (ECOG 0-1).
- Your kidney tumor can be removed with surgery, and you have at least one other tumor that can be measured.
- Your cancer is in an intermediate or high-risk category (IMDC risk group).
- You have not yet received any systemic treatment (like chemo or immunotherapy) for your advanced cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial studies people with advanced (metastatic) kidney cancer who are starting a specific set of first-line treatment combinations (including drugs like nivolumab, pembrolizumab, or avelumab, paired with targeted medicines). It may help improve how these treatment plans work for different types of kidney cancer.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
Hear when a new Metastatic Renal Cell Carcinoma ( mRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.